Skip navigation

Jason Lettmann
General Partner

Jason Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics Ltd., Carrick Therapeutics Ltd., FIRE1 Ltd., Promedior Inc., Ra Pharmaceuticals Inc., Relievant Medsystems Inc., Second Genome Inc., and Vapotherm Inc. Jason also established Lightstone’s Europe office in 2014 located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.

Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.

Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.


M.B.A. with distinction from the University of Michigan’s Ross School of Business
B.A. with honors from the University of Iowa


  • 11.10.17
    Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

    Data presented at the Annual Meeting of the Society for Immunotherapy of...

  • 04.10.17
    Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

    Alexo Therapeutics, a clinical-stage immuno-oncology company developing...

  • 11.17.16
    Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria